Immunovant (IMVT) Return on Capital Employed (2019 - 2026)
Immunovant's (IMVT) quarterly Return on Capital Employed came in at 5.08% in Q1 2026, down 7733.0% YoY from 0.07% in Q1 2025, and up 1540.45% on a QoQ basis from 0.35% in Q4 2025.
Immunovant (IMVT) Return on Capital Employed (2019 - 2026) Analysis & Trends
Immunovant (IMVT) has 8 years of Return on Capital Employed data on file, last reported at 5.08% in Q1 2026.
- Quarterly Return on Capital Employed fell 7733.0% year-over-year to 5.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.08% (down 7733.0% YoY) and the FY2026 annual result came in at 25.37%, up 438.0% from the prior year.
- Return on Capital Employed grew to 5.08% in Q1 2026, from 0.35% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 170.91% in Q4 2023 to a low of 41.8% in Q3 2022.
- A 5-year average of 47.03% and a median of 30.04% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed jumped 21114 bps — and 2024, when it sank 10792 bps.
- Tracing IMVT's Return on Capital Employed over 5 years: stood at 20.1% in 2022, then surged by 950 bps to 170.91% in 2023, then plunged by 63 bps to 62.98% in 2024, then sank by 101 bps to 0.35% in 2025, then jumped by 1540 bps to 5.08% in 2026.
- The last three Return on Capital Employed figures came in at 5.08% (Q1 2026), 0.35% (Q4 2025), and 10.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | -10.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.78% |
| Mar 31, 2026 | 5.08% |
| Dec 31, 2025 | -0.35% |
| Sep 30, 2025 | 10.23% |
| Jun 30, 2025 | 39.20% |
| Mar 31, 2025 | 82.41% |
| Dec 31, 2024 | 62.98% |
| Sep 30, 2024 | 115.61% |
| Jun 30, 2024 | 131.86% |
| Mar 31, 2024 | 109.23% |
| Dec 31, 2023 | 170.91% |
| Sep 30, 2023 | 169.34% |
| Jun 30, 2023 | 30.04% |
| Mar 31, 2023 | -0.53% |
| Dec 31, 2022 | -20.10% |
| Sep 30, 2022 | -41.80% |
| Jun 30, 2022 | -34.80% |
| Mar 31, 2022 | -29.80% |
| Dec 31, 2021 | -24.08% |
| Sep 30, 2021 | -26.01% |